Third Amendment to Guarantee Fee, Reimbursement and Indemnification Agreement



 Exhibit 10.1 
 THIRD AMENDMENT TO GUARANTEE FEE, 
 REIMBURSEMENT AND INDEMNIFICATION AGREEMENT

 This THIRD AMENDMENT dated as of November 16, 2007 (this “Third Amendment”) to the Guarantee Fee,
Reimbursement Agreement and Indemnification Agreement dated as of March 16, 2007, as amended on April 17, 2007 and on May 16, 2007 (as amended, the “Guarantee Fee Agreement”), by and among MEDICAL SOLUTIONS
MANAGEMENT INC., a corporation organized and existing under the laws of the State of Nevada (the “MSMI”), ORTHOSUPPLY MANAGEMENT, INC., a Delaware corporation (the “Guarantor”) and VICIS CAPITAL MASTER
FUND, a sub-trust of Vicis Capital Series Master Trust, a unit trust organized and existing under the laws of the Cayman Islands (the “Fund”). All capitalized terms used herein and not otherwise defined shall have the meaning
ascribed to them in the Guarantee Fee Agreement. 
 WITNESSETH: 
 WHEREAS, MSMI proposes to enter into an amendment, in the form of Exhibit A attached hereto, to the Irrevocable Standby Letter of Credit
No. 00034 in favor of the Bank (as amended and in effect from time to time, the “Letter of Credit”) to change the expiration date from March 15, 2008 to March 15, 2009 (the “Letter of Credit Amendment”).

 WHEREAS, pursuant to the terms of the Guarantee Fee Agreement, MSMI may not amend the Letter of Credit without the prior written consent
of the Fund; and 
 WHEREAS, as consideration for the Fund’s consent to the Letter of Credit Amendment, MSMI has agreed to issue to the
Fund warrants, in the form attached hereto as Exhibit B (the “LC Amendment Warrant”) to purchase an aggregate of 3,060,000 shares of Common Stock (the “LC Amendment Warrant Shares”), upon the terms and
conditions hereinafter set forth. 
 Accordingly, in consideration of the mutual promises and covenants hereinafter set forth, the parties
hereto agree as set forth below. 
 OPERATIVE PROVISIONS 
 1. Issuance of LC Amendment Warrant. Reference is hereby made to that certain letter agreement, of even date herewith, by and between MSMI
and the Fund (the “Letter Agreement”) providing for the issuance of the LC Amendment Warrant by MSMI to the Fund. Pursuant to the terms of the Letter Agreement, immediately upon and subject to the effectiveness in the State of
Nevada of the amendment to MSMI’s Amended and Restated Articles of Incorporation (as so amended and restated, the “Articles of Incorporation”) increasing the number of authorized but unissued shares of Common Stock (the
“Charter Amendment”), MSMI shall issue the LC Amendment Warrant to the Fund. 
 2. Representations and Warranties.
MSMI and Guarantor hereby, jointly and severally, represent and warrant to the Fund as of the date of this Third Amendment as follows: 
 (a) Issuance of Securities. Subject to the effectiveness of the Charter Amendment as described in Section 1 hereof, MSMI has authorized the issuance of the LC Amendment Warrant, 








 
and, if and when so issued, the LC Amendment Warrant will be validly issued, fully paid and nonassessable and will be free from all taxes, Liens and charges
with respect to the issue thereof. Subject to the effectives of the Charter Amendment as described in Section 1 hereof, MSMI will have authorized and reserved 3,060,000 shares of Common Stock for the issuance upon exercise of the LC Amendment
Warrant. The LC Amendment Warrant Shares, if and when issued and paid for upon exercise, if any, of the LC Amendment Warrant, will be validly issued, fully paid and nonassessable and free from all taxes, Liens and charges with respect to the issue
thereof, with the holders thereupon being entitled to all rights accorded to a holder of the Common Stock. All requisite corporate action by and on the part of MSMI necessary for the valid issuance of the LC Amendment Warrant and the LC Amendment
Warrant Shares has been taken. 
 (b) Authorization; Enforcement; Validity. MSMI has the requisite corporate power and
authority to enter into and perform its obligations under this Third Amendment, the LC Amendment Warrant (subject to the effectiveness of the Charter Amendment as described in Section 1 hereof), and each of the other agreements or instruments
entered into by the parties hereto in connection with the transactions contemplated by this Third Amendment (collectively, the “Transaction Documents”). The Transaction Documents have been duly executed and delivered by MSMI, and
constitute the legal, valid and binding obligations of MSMI enforceable against MSMI in accordance with their respective terms, except (i) as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies, and (ii) as any rights to indemnity or contribution hereunder may be
limited by federal and state securities laws and public policy consideration. 
 (c) No Conflicts. The execution,
delivery and performance of the Transaction Documents by MSMI and the consummation by MSMI of the transactions contemplated hereby and thereby (including, without limitation, the reservation for issuance of the LC Amendment Warrant Shares) will not
(i) subject to the effectiveness of the Charter Amendment as described in Section 1 hereof, result in a violation of the Articles of Incorporatoin or bylaws of MSMI or the certificate of incorporation or bylaws of the Guarantor or
(ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material agreement,
indenture or instrument to which MSMI or the Guarantor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to MSMI or the
Guarantor or by which any property or asset of MSMI or the Guarantor is bound or affected, except in the case of clauses (ii) and (iii), for such breaches or defaults as would not be reasonably expected to have a Material Adverse Effect.

 (d) Placement Agent’s Fees. No brokerage or finder’s fee or commission are or will be payable to any
Person with respect to the transactions contemplated by this Third Amendment based upon arrangements made by MSMI or any of its affiliates. MSMI agrees that it shall be responsible for the payment of any placement agent’s fees, financial
advisory fees, or brokers’ commissions (other than for persons engaged by the Fund) relating to or arising out of the transactions contemplated hereby. MSMI shall pay, and hold the Fund harmless against, any liability, loss or expense
(including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any claim for any such fees or commissions. 
 (e) Confirmation of Representation, Warranties, Covenants. Except as disclosed in the reports, schedules, forms, statements and other documents filed by MSMI since March 16, 2007 with the Securities and
Exchange Commission pursuant to the reporting requirements of the 

  

 -2- 








 
Securities Exchange Act of 1934, as amended, (i) each representation and warranty made by MSMI or the Guarantor in the Guaranty Fee Agreement is true
and correct in all material respects as if made as of the date hereof, except for those made with reference to a certain date which has now passed and except that OrthSupply Management LLC, a Massachusetts limited liability company, is no longer a
subsidiary of the Guarantor, and (ii) MSMI and the Guarantor have fully complied in all material respects with each covenant in the Guaranty Fee Agreement. 
 3. Section 9.1 Events of Default. The following are added to the end of Section 9.1, as additional Events of Default: 
 (i) if MSMI fails to file the Charter Amendment with the State of Nevada and issue the LC Amendment Warrant by February 15, 2008; or

 (j) if, without written consent of the Fund, the Letter of Credit is extended beyond March 15, 2009, whether by
automatic renewal, request of MSMI, or otherwise. 
 4. Consent. By its signature below, the Fund hereby consents to the Letter of
Credit Amendment. 
 5. Ratification of Agreement. The terms and conditions of the Guarantee Fee Agreement that have not been modified
by this Third Amendment shall remain in full force and effect against MSMI, Guarantor, and the Fund. 
 6. Counterparts. This Third
Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. 
 [signature page to follow on next page] 
  

 -3- 








 IN WITNESS WHEREOF, this Third Amendment has been executed by the parties hereto the day and year first
above written. 
  

			
	MSMI:
	
	MEDICAL SOLUTIONS MANAGEMENT INC.,
	a Nevada Corporation
		
	By:	 	 /s/ Brian Lesperance

		 	Brian Lesperance, Chief Executive Officer
	
	GUARANTOR:
	
	ORTHOSUPPLY MANAGEMENT, INC.,
	a Delaware corporation
		
	By:	 	 /s/ Brian Lesperance

		 	Brian Lesperance, Chief Executive Officer
	
	FUND:
	
	VICIS CAPITAL MASTER FUND, a sub-trust of Vicis Capital Series Master Trust
		
	By:	 	Caledonian Bank & Trust Limited,
		 	Trustee of Vicis Capital Series Master Trust
		
	By:	 	 /s/ Keith W. Hughes

	Name:	 	Keith W. Hughes
	Title:	 	Chief Financial Officer









 EXHIBIT A 
 IRREVOCABLE STANDBY LETTER OF CREDIT NO. 00034 
 AMENDMENT NO. 2 
 AMENDMENT DATE: NOVEMBER 16, 2007 
  

			
	BENEFICIARY:	 	APPLICANT:
		
	 SOVEREIGN BANK
 3 FRIENDS LANE, 3RD FLOOR
 NEWTOWN, PA 18940
 ATTENTION: STANDBY LETTER OF CREDIT DEPARTMENT
	 	 MEDICAL SOLUTIONS MANAGEMENT INC.
 237 CEDAR HILL STREET

 MARLBOROUGH, MA 01752


 GENTLEMEN/LADIES: 
 WE
HEREBY, BY MEANS OF THIS AMENDMENT NO. 2, AMEND OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. 00034 ORIGINALLY ISSUED ON MARCH 16, 2007 (AS AMENDED BY AMENDMENT NO. 1 THERETO DATED AS OF MAY 15, 2007, THE “LETTER OF
CREDIT”) AS FOLLOWS: 
  

	 	(A)	BY AMENDING AND RESTATING THE “EXPIRATION DATE” SECTION THEREOF IN ITS ENTIRETY TO READ AS FOLLOWS: 

  

			
	“EXPIRATION DATE:	  	 MARCH 15, 2008, SUBJECT TO AUTOMATIC ONE-YEAR RENEWAL AS SET FORTH BELOW, BUT IN ANY EVENT NO LATER THAN MARCH 15, 2009.
  
 THIS LETTER OF CREDIT SHALL BE DEEMED AUTOMATICALLY EXTENDED, WITHOUT AMENDMENT, FOR AN ADDITIONAL
PERIOD OF ONE (1) YEAR FROM THE EXPIRATION DATE, UNLESS AT LEAST THIRTY (30) DAYS PRIOR TO THE EXPIRATION DATE WE NOTIFY YOU IN WRITING, BY REGISTERED MAIL, AT YOUR ADDRESS STATED ABOVE OR SUCH OTHER ADDRESS OF WHICH YOU NOTIFY US IN
WRITING BY REGISTERED MAIL FROM TIME TO TIME, OF OUR INTENTION NOT TO RENEW THIS LETTER OF










			
		  	CREDIT FOR ANY SUCH ADDITIONAL PERIOD. SUCH NOTICE OF OUR INTENTION TO NOT RENEW THIS LETTER OF CREDIT SHALL AUTHORIZE YOU TO DRAW UPON THIS LETTER OF CREDIT WITHOUT THE NEED TO DELIVER THE
WRITTEN STATEMENT DESCRIBED BELOW.”; AND

  

	 	 (B)
	 BY DELETING THE PHRASE “THIS LETTER OF CREDIT EXPIRES ON MARCH 15, 2008” CONSTITUTING THE 2ND PARAGRAPH THEREOF. 


 THIS AMENDMENT NO.
2 TO THE LETTER OF CREDIT SHALL BE ATTACHED TO THE LETTER OF CREDIT, AND FORM ONE INSTRUMENT THEREWITH. EXCEPT AS MODIFIED EXACTLY AS SET FORTH IN THE IMMEDIATELY PRECEDING PARAGRAPH, ALL TERMS AND CONDITIONS OF THE LETTER OF CREDIT SHALL CONTINUE
TO BE IN FULL FORCE AND EFFECT. 
 VERY TRULY YOURS, 
 CUSTODIAL
TRUST COMPANY 
  

	
	  

	BEN J. SZWALBENEST
	PRESIDENT








 Exhibit B 
 THIS WARRANT OR THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO, (ii) AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED, (iii) RECEIPT OF A NO-ACTION LETTER(S) FROM THE APPROPRIATE GOVERNMENTAL
AUTHORITY(IES), OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT. 
 THIS WARRANT AND THE SECURITIES ISSUABLE
UPON EXERCISE OF THIS WARRANT ARE SUBJECT TO CERTAIN RESTRICTIONS SET FORTH IN THAT CERTAIN LOCK-UP AND LEAK-OUT AGREEMENT, DATED AS OF JUNE 28, 2006, AS MAY BE AMENDED OR MODIFIED FROM TIME TO TIME, BY AND BETWEEN MEDICAL SOLUTIONS MANAGEMENT
INC. AND THE HOLDER. 
 SERIES CS WARRANT TO PURCHASE SHARES 
 OF COMMON STOCK 
  

			
	 Warrant Number
	  	CS-
		
	 Date of Grant
	  	                                    ,
200         (the “Grant Date”)
		
	 Exercise Term
	  	The purchase right represented by this Warrant is exercisable, in whole or in part, at any time from the Grant Date and from time to time thereafter through and including the close of
business on the date five (5) years from the Grant Date (the “Expiration Date”); provided, however, that in the event that any portion of this Warrant is unexercised as of the Expiration Date, the terms of Section
2(b) of this Warrant shall apply.
		
	 Name of Holder
	  	Vicis Capital Master Fund
		
	 Right to Purchase the following number of shares of Common Stock of Medical Solutions Management Inc. (subject to adjustment as provided
herein)
	  	3,060,000
		
	 Warrant Price
	  	$0.50

  

 Page 1 








 Medical Solutions Management Inc., a Nevada corporation (the “Company”), hereby certifies that, for
value received, the “Holder” identified in the table above, or its registered assigns, is the registered holder of a warrant (the “Warrant”) to subscribe for and purchase the number of fully paid and nonassessable
Common Stock set forth in the table above (as adjusted pursuant to Section 4 hereof, the “Warrant Shares”) of the Company, at a price per share equal to $0.50 (such price and such other price as shall result, from time
to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions hereinafter set forth. 
 As used herein, (a) the term “Common Stock” shall mean the Company’s presently authorized Common Stock, par value $0.0001 per
share, and any stock into or for which such Common Stock may hereafter be converted or exchanged, and (b) the term “Other Warrants” shall mean any warrant issued upon transfer or partial exercise of this Warrant. The term
“Warrant” as used herein shall be deemed to include Other Warrants unless the context hereof or thereof clearly requires otherwise. 
  

	 	1.	Term. The term of the purchase right represented by this Warrant as set forth in the table above. 

  

	 	2.	Exercise; Expiration; Redemption. 

 a. Method of
Exercise; Payment; Issuance of New Warrant. Subject to Section 1 hereof, the purchase right represented by this Warrant may be exercised by the Holder, in whole or in part and from time to time after the Initial Exercise Date, by the
surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A duly executed) at the principal office of the Company and by the payment to the Company of an amount equal to the then applicable Warrant Price
multiplied by the number of Warrant Shares then being purchased. The person or persons in whose name(s) any certificate(s) representing shares of Common Stock shall be issuable upon exercise of this Warrant shall be deemed to have become the
holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which
this Warrant is exercised. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be delivered to the Holder as soon as possible and in any event within thirty (30) days
after such exercise and, unless this Warrant has been fully exercised, a new Warrant representing the portion of the Warrant Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be issued to the Holder as
soon as possible and in any event within such thirty (30)-day period. 
  

 Page 2 








 b. Expiration. In the event that any portion of this Warrant is unexercised as of the Expiration
Date, such portion of this Warrant shall automatically expire, and the Holder shall have no rights with respect to such unexercised portion of this Warrant. 
 c. Maximum. In no event shall the Holder be entitled to exercise any Warrant Shares to the extent that, after such exercise, the sum of the number of shares of Common Stock beneficially owned by the Holder and
its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unexercised portion of the Warrant Shares or any unexercised right held by the Holder subject to a similar limitation), would
result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock (after taking into account the shares to be issued to the Holder upon such exercise). For purposes of this
Section 2(c), beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended. Nothing herein shall preclude the Holder from disposing of a sufficient number of other
shares of Common Stock beneficially owned by the Holder so as to thereafter permit the continued exercise of this Warrant. 
 d. Cashless
Exercise. Subject to the provisions hereof, at any time or from time to time prior to the Expiration Date, the Holder shall also have the right to exercise this Warrant or any portion thereof, without payment by the Holder of the Warrant Price
in cash or any other consideration (other than the surrender of rights to receive Warrant Shares hereunder), as provided herein (a “Cashless Exercise”). Upon a Cashless Exercise with respect to a particular number of Warrant Shares
(the “Exchanged Warrant Shares”), the Company shall deliver to the Holder (without payment by the Holder of the Warrant Price in cash or any other consideration (other than the surrender of rights to receive Common Stock hereunder)
that number of Warrant Shares computed using the following formula: 
  

			
	X =	  	 Y (A - B)

		  	A

  

					
	Where:	  	X =	  	the number of Warrant Shares to be delivered to the holder;
		  	Y =	  	the number of Exchanged Warrant Shares;
		  	A =	  	the Fair Market Value of the Warrant Shares as determined in accordance with Section 4.
		  	B =	  	the Warrant Price (as adjusted through the Cashless Exercise Date)


 A Cashless Exercise may be effected by the Holder by the surrender of this Warrant as
provided herein, together with a written statement specifying that the Holder thereby intends to effect a Cashless Exercise and indicating the number of Exchanged Warrant Shares which are covered by the Cashless Exercise. Such Cashless Exercise
shall be effective 

  

 Page 3 








 
upon receipt by the Company of this Warrant, together with the aforesaid written statement, or on such later date as is specified therein (the
“Cashless Exercise Date”). The Company shall issue to the Holder as of the Cashless Exercise Date a certificate for the Warrant Shares issuable upon the Cashless Exercise and, if applicable, a new warrant of like tenor evidencing
the balance of the Warrant Shares remaining subject to this Warrant. 
 3. Stock Fully Paid; Reservation of Shares. All Warrant Shares
that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all taxes (other than any taxes determined with respect
to, or based upon, the income of the person to whom such shares are issued), liens and charges (other than liens or charges created by actions of the Holder or the person to whom such shares are issued), and pre-emptive rights with respect to the
issue thereof. During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights evidenced by this
Warrant, a sufficient number of shares of its Common Stock to provide for the exercise of the rights represented by this Warrant. 
 4.
Adjustment of Warrant Price and Number of Shares. The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as
follows: 
 a. Reclassification or Merger. In case of any reclassification, change or conversion of securities of the class issuable
upon exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another
corporation (other than a merger with another corporation in which the Company is the acquiring and the surviving corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this
Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to the Holder a new Warrant (in form and
substance satisfactory to the Holder), so that the Holder shall have the right to receive, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the shares of Common Stock
theretofore issuable upon exercise of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable upon such reclassification, change or merger by a holder of the number of shares of Common Stock then
purchasable under this Warrant. Such new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 4. The provisions of this Section 4(a)
shall similarly apply to successive reclassifications, changes, mergers and transfers. 
  

 Page 4 








 b. Subdivision or Combination of Shares. If at any time while this Warrant remains outstanding and
unexpired the Company shall subdivide or combine its outstanding shares of Common Stock, the Warrant Price shall be proportionately decreased in the case of a subdivision or increased in the case of a combination, effective at the close of business
on the date the subdivision or combination becomes effective. 
 c. Stock Dividends. If at any time while this Warrant is outstanding
and unexpired the Company shall pay a dividend with respect to Common Stock payable in Common Stock, then the Warrant Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or
distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (i) the numerator of which shall be the total number of shares of Common Stock outstanding
immediately prior to such dividend, and (ii) the denominator of which shall be the total number of shares of Common Stock outstanding immediately after such dividend. 
 d. Rights Offerings. In case the Company shall, at any time after the Grant Date, issue rights, options or warrants to the holders of equity
securities of the Company, entitling them to subscribe for or purchase shares of Common Stock (or securities convertible or exchangeable into Common Stock) at a price per share of Common Stock (or having a conversion or exchange price per share of
Common Stock if a security convertible or exchangeable into Common Stock) less than the Warrant Price in effect on the record date for such issuance (or the date of issuance, if there is no record date), the Warrant Price to be in effect on and
after such record date (or issuance date, as the case may be) shall be reduced, concurrently with such issue, to a price equal to the consideration received per share in connection with the issuance of such Additional Shares of Common Stock. In case
such purchase or subscription price may be paid in part or in whole in a form other than cash, the fair value of such consideration shall be determined by the Board of Directors of the Company (the “Board of Directors”) in good
faith as set forth in a duly adopted board resolution certified by the Company’s Secretary or Assistant Secretary. Such adjustment shall be made successively whenever such an issuance occurs; and in the event that such rights, options,
warrants, or convertible or exchangeable securities are not so issued or expire or cease to be convertible or exchangeable before they are exercised, converted, or exchanged (as the case may be), then the Warrant Price shall again be adjusted to be
the Warrant Price that would then be in effect if such issuance had not occurred, provided however, the Company shall adjust the number of Warrant Shares issued upon any exercise of this Warrant after the adjustment required pursuant
to this Section 4(d) but prior to the date such subsequent adjustment is made, in order to equitably reflect the fact that such rights, options, warrants, or convertible or exchangeable securities were not so issued or expired or ceased
to be convertible or exchangeable before they were exercised, converted, or exchanged (as the case may be). 
  

 Page 5 








 e. Other Issuances of Securities. In case the Company or any subsidiary of the Company shall, at
any time after the Grant Date, issue shares of Common Stock, or rights, options, warrants or convertible or exchangeable securities containing the right to subscribe for or purchase shares of Common Stock (excluding (i) shares, rights, options,
warrants, or convertible or exchangeable securities or issued in any of the transactions described in Sections 4(a), 4(b), 4(c), or 4(d) above, (ii) shares issued upon the exercise of such rights, options or
warrants or upon conversion or exchange of such convertible or exchangeable securities, and (iii) this Warrant and any shares issued upon exercise thereof), at a price per share of Common Stock (determined in the case of such rights, options,
warrants, or convertible or exchangeable securities by dividing (x) the total amount receivable by the Company in consideration of the sale and issuance of such rights, options, warrants, or convertible or exchangeable securities, plus the
total minimum consideration payable to the Company upon exercise, conversion, or exchange thereof by (y) the total maximum number of shares of Common Stock covered by such rights, options, warrants, or convertible or exchangeable securities)
lower than the Warrant Price in effect on the date of such issuance, then the Warrant Price shall be reduced, concurrently with such issue, to a price equal to the consideration received per share in connection with the issuance of such Additional
Shares of Common Stock. For the purposes of such adjustment, the maximum number of shares of Common Stock which the holder of any such rights, options, warrants or convertible or exchangeable securities shall be entitled to subscribe for or purchase
shall be deemed to be issued and outstanding as of the date of such sale and issuance and the consideration received by the Company therefor shall be deemed to be the consideration received by the Company for such rights, options, warrants, or
convertible or exchangeable securities, plus the minimum consideration or premium stated in such rights, options, warrants, or convertible or exchangeable securities to be paid for the shares of Common Stock covered thereby. In case the Company
shall sell and issue shares of Common Stock, or rights, options, warrants, or convertible or exchangeable securities containing the right to subscribe for or purchase shares of Common Stock for a consideration consisting, in whole or in part, of
property other than cash or its equivalent, then in determining the price per share of Common Stock and the consideration received by the Company for purposes of the first sentence of this Section 4(e), the Board of Directors shall
determine, in good faith, the fair value of said property, and such determination shall be described in a duly adopted board resolution certified by the Company’s Secretary or Assistant Secretary. In case the Company shall sell and issue
rights, options, warrants, or convertible or exchangeable securities containing the right to subscribe for or purchase shares of Common Stock together with one (1) or more other securities as a part of a unit at a price per unit, then in
determining the price per share of Common Stock and the consideration received by the Company for purposes of the first sentence of this Section 4(e), the Board of Directors 

  

 Page 6 








 
shall determine, in good faith, which determination shall be described in a duly adopted board resolution certified by the Company’s Secretary or
Assistant Secretary, the fair value of the rights, options, warrants, or convertible or exchangeable securities then being sold as part of such unit. Such adjustment shall be made successively whenever such an issuance occurs, and in the event that
such rights, options, warrants, or convertible or exchangeable securities expire or cease to be convertible or exchangeable before they are exercised, converted, or exchanged (as the case may be), then the Warrant Price shall again be adjusted to
the Warrant Price that would then be in effect if such sale and issuance had not occurred, but such subsequent adjustment shall not affect the number of Warrant Shares issued upon any exercise of this Warrant prior to the date such subsequent
adjustment is made. 
 f. Adjustment of Number of Shares. Upon each adjustment in the Warrant Price, the number of Warrant Shares
purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Warrant Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the numerator of which
shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 
 g. Determination of Fair Market Value. For purposes of this Warrant, “fair market value” of a share of Common Stock as of a particular date (the “Determination Date”) shall mean (i) if shares of
Common Stock are traded on a national securities exchange (an “Exchange”), the weighted average of the closing sale price of a share of the Common Stock of the Company on the last five (5) trading days prior to the
Determination Date reported on such Exchange as reported in The Wall Street Journal (weighted with respect to the trading volume with respect to each such day), (ii) if shares of Common Stock are not traded on an Exchange but trade in
the over-the-counter market and such shares are quoted on the National Association of Securities Dealers Automated Quotations System (“NASDAQ”), the weighted average of the closing sale price of a share of the Common Stock of the
Company on the last five (5) trading days prior to the Determination Date reported on NASDAQ as reported in The Wall Street Journal (weighted with respect to the trading volume with respect to each such day), (iii) if such shares
are an issue for which last sale prices are not reported on NASDAQ, the average of the closing sale price, in each case on the last five (5) trading days (or if the relevant price or quotation did not exist on any of such days, the relevant
price or quotation on the next preceding business day on which there was such a price or quotation) prior to the Determination Date as reported by the Over the Counter Bulletin Board (the “OTCBB”), the National Quotation Bureau,
Incorporated, or any other successor organization, (iv) if no closing sales price is reported for the Common Stock by the OTCBB, National Quotation Bureau, Incorporated or any other successor organization for such day, the average of the high
and low bid and asked price of any of the market makers for the Common Stock as reported on the OTCBB or 

  

 Page 7 








 
in the “pink sheets” by the Pink Sheets, LLC on the last five (5) trading days, or (v) if no price can be determined on the basis of the
above methods of valuation, then the judgment of valuation shall be determined in good faith by the Board of Directors, which determination shall be described in a duly adopted board resolution certified by the Company’s Secretary or Assistant
Secretary. If the Board of Directors is unable to determine any Valuation (as defined below), or if the Holder disagrees with the Board of Directors’ determination of any Valuation by written notice delivered to the Company within five
(5) business days after the determination thereof by the Board of Directors is communicated to the Holder, which notice specifies the Holder’s determination of such Valuation, then the Company and the Holder shall select a mutually
acceptable investment banking firm of national reputation which has not had a material relationship with the Company or any officer of the Company within the preceding two (2) years, which shall determine such Valuation. Such investment banking
firm’s determination of such Valuation shall be final, binding and conclusive on the Company and the Holder. Any and all costs and fees of such investment banking firm shall be borne equally by the Company and the Holder, however, if the
Valuation is within 90% of either party’s valuation, then the other party shall pay all of the costs and fees of such investment banking firm. For purposes of this Section 4(g), the term “Valuation” shall mean the
determination, to be made initially by the Board of Directors, of the fair market value per share of Common Stock pursuant to clause (v) above. 
 h. Subsequent Changes. If, at any time after any adjustment of the Warrant Price shall have been made hereunder as the result of any issuance, sale or grant of any rights, options, warrants or convertible or
exchangeable securities, any of such rights, options or warrants or the rights of conversion or exchange associated with such convertible or exchangeable securities shall expire by their terms or any of such rights, options, warrants or convertible
or exchangeable securities shall be repurchased by the Company or a subsidiary of the Company for a consideration per underlying share of Common Stock not exceeding the amount of such consideration received by the Company in connection with the
issuance, sale or grant of such rights, options, warrants or convertible or exchangeable securities, the Warrant Price then in effect shall forthwith be increased to the Warrant Price that would have been in effect if such expiring right, option or
warrant or rights of conversion or exchange or such repurchased rights, options, warrants or convertible or exchangeable securities had never been issued. Similarly, if at any time after any such adjustment of the Warrant Price shall have been made
pursuant to Section 4(e) above (i) any additional aggregate consideration is received or becomes receivable by the Company in connection with the issuance of exercise of such rights, options, warrants or convertible or exchangeable
securities or (ii) there is a reduction in the conversion or exchange ratio applicable to such convertible or exchangeable securities so that fewer shares of Common Stock will be issuable upon the conversion or exchange thereof or there is a
decrease in the number of shares of Common Stock issuable upon exercise of such rights, options or 

  

 Page 8 








 
warrants (except where such reduction or decrease results from a combination of shares described in Section 4(b) above), the Warrant Price then
in effect shall be forthwith readjusted to the Warrant Price that would have been in effect had such changes taken place at the time that such rights, options, warrants or convertible or exchangeable securities were initially issued, granted or
sold. In no event shall any readjustment under this Section 4(h) affect the validity of any Warrant Shares issued upon any exercise of this Warrant prior to such readjustment. 
 i. Excluded Transactions. Notwithstanding the foregoing, Sections 4(d) or 4(e) above shall not apply to: (i) shares of Common Stock
issued or deemed issued to employees or directors of, or consultants to, the Company or any of its subsidiaries pursuant to a plan, agreement, or arrangement approved by the Board of Directors; provided that, at the time of any such issuance
under clause (i) above, the aggregate of such issuances under clause (i) in the then preceding 12 month period shall not exceed 3,000,000 shares of Common Stock of the Company (subject to equitable adjustment in the event a stock dividend,
stock split, combination, reclassification, or other similar event affecting the Common Stock); provided, further that, the aggregate issuance after December 30, 2005 shall not, in any event, exceed 5,580,000 (subject to equitable
adjustment in the event a stock dividend, stock split, combination, reclassification, or other similar event affecting the Common Stock); (ii) the issuance of securities pursuant to the conversion or exercise of convertible or exercisable
securities outstanding on the date hereof; (iii) shares of Common Stock issued in connection with any stock split or stock dividend of the Company; (iv) the issuance of shares of Common Stock in connection with a bona fide joint venture or
business acquisition of or by the Company approved by the Board of Directors, whether by merger, consolidation, sale of assets, sale or exchange of stock, or otherwise; provided that, at the time of any such issuance under clause
(iv) above, the aggregate of such issuances under clause (iv) in the preceding 12 month period shall not exceed 10% of the then outstanding Common Stock (assuming full conversion and exercise of all convertible and exercisable securities);
and (v) the issuance of shares of Common Stock upon exercise of any of the warrants of the Company outstanding as of the Grant Date (or issuable pursuant to other convertible securities of the Company outstanding as of the Grant Date).

 5. Notice of Adjustments. Whenever the Warrant Price or the number of Warrant Shares purchasable hereunder shall be adjusted
pursuant to Section 4 hereof, the Company shall deliver to the Holder a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method
by which such adjustment was calculated, and the Warrant Price and the number of Warrant Shares purchasable hereunder after giving effect to such adjustment. 
 6. Fractional Shares. No fractional shares of Common Stock will be issued in connection with any exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor based on
the fair market value (as determined in accordance with Section 4(g) above) of a share of Common Stock on the date of exercise. 
  

 Page 9 








 7. Compliance with Securities Act; Disposition of Warrant or Warrant Shares. 
 a. Compliance with Securities Act. The Holder, by acceptance hereof, agrees that this Warrant and the shares of Common Stock to be issued upon
exercise hereof are being acquired for investment and that the Holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Common Stock to be issued upon exercise hereof except under circumstances which will not result in a
violation of the Securities Act of 1933, as amended (the “Securities Act”). Upon exercise of this Warrant, the Holder shall confirm in writing, by executing the form attached as Exhibit A hereto, that the shares of Common
Stock so purchased are being acquired for investment and not with a view toward distribution or resale. This Warrant and all shares of Common Stock issued upon exercise of this Warrant (unless registered under the Securities Act) shall be stamped or
imprinted with a legend in substantially the following form: 
 “THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO, (ii) AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY, THAT
SUCH REGISTRATION IS NOT REQUIRED, (iii) RECEIPT OF A NO-ACTION LETTER(S) FROM THE APPROPRIATE GOVERNMENTAL AUTHORITY(IES), OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT UNDER WHICH THESE SECURITIES
WERE ISSUED DIRECTLY OR INDIRECTLY.” 
 In addition, in connection with the issuance of this Warrant, the Holder specifically represents to the Company
by acceptance of this Warrant as follows: 
 (1) The Holder is aware of the Company’s business affairs and financial condition, and has
acquired information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant. The Holder has executed a confidentiality agreement and will hold all information governed by that agreement in accordance
with the terms of such agreement. The Holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution” thereof for purposes of the Securities
Act. 
  

 Page 10 








 (2) The Holder understands that this Warrant and the Warrant Shares have not been registered under the
Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. In this connection, the Holder understands that, in
the view of the Securities and Exchange Commission (the “SEC”), the statutory basis for such exemption may be unavailable if the Holder’s representation was predicated solely upon a present intention to hold this Warrant and the
Warrant Shares for the minimum capital gains period specified under applicable tax laws, for a deferred sale, for or until an increase or decrease in the market price of this Warrant and the Warrant Shares, or for a period of one (1) year or
any other fixed period in the future. 
 (3) The Holder further understands that this Warrant and the Warrant Shares must be held
indefinitely unless subsequently registered under the Securities Act and any applicable state securities laws, or unless exemptions from registration are otherwise available. 
 (4) The Holder is aware of the provisions of Rule 144 and 144A, promulgated under the Securities Act, which, in substance, permit limited public resale
of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions, if applicable, including, among other
things: the availability of certain public information about the Company, the resale occurring not less than one (1) year after the party has purchased and paid for the securities to be sold; the sale being made through a broker in an
unsolicited “broker’s transaction” or in transactions directly with a market maker (as said term is defined under the Securities Exchange Act of 1934, as amended) and the amount of securities being sold during any three-month period
not exceeding the specified limitations stated therein. 
 (5) The Holder further understands that at the time it wishes to sell this Warrant
and the Warrant Shares there may be no public market upon which to make such a sale, and that, even if such a public market then exists, the Company may not be satisfying the current public information requirements of Rule 144 and 144A, and that, in
such event, the Holder may be precluded from selling this Warrant and the Warrant Shares under Rule 144 and 144A even if the one (1)-year minimum holding period had been satisfied. 
 (6) The Holder further understands that in the event all of the requirements of Rule 144 and 144A are not satisfied, registration under the Securities
Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rule 144 and 144A is not exclusive, the staff of the SEC has expressed its opinion that persons proposing to sell
private placement securities other than in a registered offering and otherwise than pursuant to Rule 144 and 144A will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and
that such persons and their respective brokers who participate in such transactions do so at their own risk. 
  

 Page 11 








 b. Exchange. This Warrant may be exchanged, without payment of any service charge, for one
(1) or more new Warrants of like tenor exercisable for the same aggregate number of shares of Common Stock upon surrender to the Company by the Holder in person or by legal representative or by attorney duly authorized in writing and, upon
issuance of the new Warrant or Warrants, the surrendered Warrant shall be cancelled and disposed of by the Company. 
 c. Disposition of
Warrant or Warrant Shares. With respect to any offer, sale or other disposition of this Warrant, or any Warrant Shares acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or Warrant Shares, the Holder and each
subsequent holder of this Warrant agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, if reasonably requested by the Company, to the effect
that such offer, sale or other disposition may be effected without registration or qualification (under the Securities Act as then in effect or any federal or state law then in effect) of this Warrant or such Warrant Shares and indicating whether or
not under the Securities Act certificates for this Warrant or such Warrant Shares to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with applicable law.
Promptly upon receiving such written notice and reasonably satisfactory opinion, if so requested, the Company, as promptly as practicable, shall notify such holder that such holder may sell or otherwise dispose of this Warrant or such Warrant
Shares, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 8(c) that the opinion of counsel for the holder is not reasonably satisfactory to the Company, the
Company shall so notify the holder promptly after such determination has been made and neither this Warrant nor any Warrant shall be sold or otherwise disposed of until such disagreement has been resolved. The foregoing notwithstanding, this Warrant
or such Warrant Shares may (i) as to such federal laws, be offered, sold or otherwise disposed of in accordance with Rule 144 and 144A under the Securities Act, provided that the Company shall have been furnished with such information as the
Company may reasonably request to provide a reasonable assurance that the provisions of Rule 144 and 144A have been satisfied and (ii) be offered, sold, distributed or otherwise transferred to any Affiliate of the Holder without regard to this
Section 7, but only if the Company is in receipt of an opinion of counsel as to the permissibility of such transfer under federal and state securities laws and an investor representation letter from the transferee, in form and substance
reasonably satisfactory to the Company. Each certificate representing this Warrant or the Warrant Shares thus transferred (except a transfer pursuant to Rule 144) shall bear a legend as to the applicable restrictions on transferability in order to
ensure compliance with such 

  

 Page 12 








 
laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order to ensure compliance with such laws. The Company may
issue stop transfer instructions to its transfer agent or, if acting as its own transfer agent, the Company may stop transfer on its corporate books, in connection with such restrictions. As used herein, “Affiliate of the Holder”
shall mean (x) any owner, shareholder, partner or member of the Holder, and (y) any other Person that directly or indirectly, through one or more intermediaries, Controls or is Controlled by or is under common Control (as such terms are
defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934, as amended) with the Holder. 
 8. Rights as Stockholders;
Information. The Holder, as such, shall not be entitled to vote or be deemed the holder of Common Stock or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained
herein be construed to confer upon the Holder, as such, any of the rights of a stockholder of the Company or any right to vote for the election of the directors or upon any matter submitted to stockholders at any meeting thereof, or to receive
notice of meetings, until this Warrant shall have been exercised and the Warrant Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. The foregoing notwithstanding, the Company will transmit to the Holder
such information, documents and reports as are generally distributed to the holders of any class or series of the securities of the Company concurrently with the distribution thereof to the stockholders. 
 9. Additional Rights. 
 9.1
Mergers. In the event that the Company undertakes to (i) sell, lease, exchange, convey or otherwise dispose of all or substantially all of its property or business, or (ii) merge into or consolidate with any other corporation (other
than a wholly-owned subsidiary of the Company), or effect any transaction (including a merger or other reorganization) or series of related transactions, in which more than fifty percent (50%) of the voting power of the Company is disposed of,
the Company will use its best efforts to provide at least thirty (30) days notice of the terms and conditions of the proposed transaction. The Company shall cooperate with the Holder in consummating the sale of this Warrant in connection with
any such transaction. 
 10. Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which enforcement of the same is sought. 
 11. Notices.
Unless otherwise specifically provided herein, all communications under this Warrant shall be in writing and shall be deemed to have been duly given (i) on the date of service if served personally on the party to whom notice is to be given,
(ii) on the day of transmission if sent by facsimile transmission to 

  

 Page 13 








 
the number shown on the books of the Company, and telephonic confirmation of receipt is obtained promptly after completion of transmission, (iii) on the
day after delivery to Federal Express or similar overnight courier, or (iv) on the fifth day after mailing, if mailed to the party to whom notice is to be given, by first class mail, registered or certified, postage prepaid, and properly
addressed, return receipt requested, to the Holder at its address as shown on the books of the Company or to the Company at the address indicated therefor on the signature page of this Warrant. The Holder or the Company may change its address for
purposes of this Section 11 by giving the other party written notice of the new address in the manner set forth herein. 
 12.
Binding Effect on Successors. This Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets, and all of the obligations of the
Company relating to the Common Stock issuable upon the exercise or conversion of this Warrant shall survive the exercise, conversion and termination of this Warrant and all of the covenants and agreements of the Company shall inure to the benefit of
the successors and assigns of the Holder. The Company will, at the time of the exercise or conversion of this Warrant, in whole or in part, upon request of the Holder but at the Company’s expense, acknowledge in writing its continuing
obligation to the Holder in respect of any rights to which the Holder shall continue to be entitled after such exercise or conversion in accordance with this Warrant; provided, that the failure of the Holder to make any such request shall not
affect the continuing obligation of the Company to the Holder in respect of such rights. 
 13. Lost Warrants or Stock Certificates.
The Company covenants to the Holder that, upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any loss, theft or destruction, upon
receipt of an executed lost securities bond or indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new
Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 
 14.
Descriptive Headings. The descriptive headings of the several paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. 
 15. Governing Law. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws
of the Commonwealth of Massachusetts (without regard to principles of conflicts of laws). 
 16. Remedies. In case any one (1) or
more of the covenants and agreements contained in this Warrant shall have been breached, the Holder (in the case of a breach by the Company), or the Company (in the case of a breach by the Holder), may proceed 

  

 Page 14 








 
to protect and enforce their or its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result
of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant. 
 17.
Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to the foregoing terms and conditions. 
 18. No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. 
 19. Assignment; Exchange of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be
transferred by the Holder by endorsement by the Holder of the form of assignment attached as Exhibit B hereto. On the surrender for exchange of this Warrant, with the Holder’s endorsement and together with an opinion of counsel
reasonably satisfactory to the Company that the transfer of this Warrant will be in compliance with applicable securities laws, the Company will, at the Holder’s sole cost and expense, including payment by the Holder of any applicable transfer
taxes, issue and deliver to or on the order of the Holder thereof a new Warrant or Warrants of like tenor, in the name of the Holder and/or the transferee(s) specified by the Holder (each, a “Transferee”), providing for in the
aggregate on the face or faces thereof the number of shares of Common Stock called for on the face or faces of this Warrant so surrendered by the Holder. Notwithstanding the foregoing, no such transfers shall result in any public distribution of
this Warrant. 
  

 Page 15 








 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed on its behalf by one of its
officers thereunto duly authorized. 
  

			
	MEDICAL SOLUTIONS MANAGEMENT INC.
		
	By:	 	 
		 	 Name:
 Title:



 Dated: November         , 2007 
  







 NOTICE TO FLORIDA RESIDENTS 
  

 WHERE SALES ARE MADE TO FIVE OR MORE PERSONS IN
FLORIDA (EXCLUDING CERTAIN INSTITUTIONAL PURCHASERS DESCRIBED IN SECTION 517.061(7) OF THE FLORIDA SECURITIES AND INVESTOR PROTECTION ACT) (THE “ACT”), ANY SUCH SALE MADE PURSUANT TO SECTION 517.061(11) OF THE ACT SHALL BE VOIDABLE BY THE
PURCHASER EITHER WITHIN THREE DAYS AFTER THE FIRST TENDER OF CONSIDERATION IS MADE BY SUCH PURCHASER TO THE ISSUER, OR AN AGENT OF THE ISSUER, OR AN ESCROW AGENT OR WITHIN THREE DAYS AFTER THE AVAILABILITY OF THAT PRIVILEGE IS COMMUNICATED TO SUCH
PURCHASER, WHICHEVER OCCURS LATER. 
  







 EXHIBIT A 
 FORM OF NOTICE OF EXERCISE 
 1. The undersigned hereby elects to purchase shares of Common
Stock of Medical Solutions Management Inc. pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full. 
 2. Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name or names as are specified
below: 
  

 (Name)

  

  


(Address) 
 3. The undersigned represents that the aforesaid
shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such
shares. 
  

	
	
	  
	(Signature)



 (Date) 
  







 EXHIBIT B 
 FORM OF ASSIGNMENT 
 (To be signed only on transfer of Warrant) 
 For value received, the undersigned hereby sells, assigns and transfers unto
                                        
         the right represented by the within Series CS Warrant No. CS-11 to purchase              shares of Common Stock of Medical
Solutions Management Inc. to which the within Series CS Warrant No. CS-11 relates, and appoints
                                        
                         Attorney-in-Fact to transfer such right on the books of Medical Solutions Management Inc., with full
power of substitution in the premises. 
 Dated: 

	
	  
	(Signature must conform to name of Holder as specified on the face of Warrant)
	  
	  
	  
	(Address)